REAC Neuromodulation Treatments in Depression, Anxiety and Stress. A Comparative Retrospective Study.
DASS-21
behavioral disorders
neuromodulation
noninvasive neurostimulation
Journal
Psychology research and behavior management
ISSN: 1179-1578
Titre abrégé: Psychol Res Behav Manag
Pays: New Zealand
ID NLM: 101514563
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
10
2020
accepted:
05
12
2020
entrez:
30
12
2020
pubmed:
31
12
2020
medline:
31
12
2020
Statut:
epublish
Résumé
The purpose of this retrospective study was to compare the effects of two different modalities of administration of the neuro psycho physical optimization (NPPO) neuromodulation treatment, applied with radio electric asymmetric conveyer (REAC) biotechnology devices. Both the modalities are aimed at improving the strategies to deal with and optimize the allostatic response to environmental stressors and exposome. This allows to reduce the dysfunctional adaptive behavior patterns, which underlie many neuropsychological symptoms and pathologies, and to improve the symptoms of depression, anxiety and stress. From a population of subjects experiencing at least two of the three symptoms depression, anxiety and stress, the selection of pre and post-treatment Depression, Anxiety, Stress 21 items scale (DASS 21) data was made proceeding with a reverse chronological recruitment mechanism, until reaching 150 subjects for each of the 2 groups. The first group was treated with the neuro psycho physical optimization treatment (NPPO), which is the punctiform modality of administration on the auricle pavilion, and the second group was treated with the neuro psycho physical optimization treatment, which is the area modality of administration applied by the planar probe on the cervicobrachial area (NPPO-CB). The Wilcoxon signs test confirmed the differences in scores in pre and post-treatment DASS-21. The comparison between the two groups data and the comparison across groups data showed that NPPO and NPPO-CB have the same efficacy in reducing the symptoms of depression, anxiety and stress, after a single treatment cycle. Statistical significance was set at p <0.05. This is the first efficacy descriptive comparison between the two different modalities of administration of the NPPO treatment, as different options for the same clinical indication.
Identifiants
pubmed: 33376420
doi: 10.2147/PRBM.S287143
pii: 287143
pmc: PMC7762445
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1247-1256Informations de copyright
© 2020 Pinheiro Barcessat et al.
Déclaration de conflit d'intérêts
A.R. is the daughter of Salvatore Rinaldi and Vania Fontani, authors of the REAC technology patent and reports no other potential conflicts of interest for this work. The other authors declare no conflicts of interest.
Références
BMC Musculoskelet Disord. 2009 Jan 26;10:13
pubmed: 19171034
Turk J Med Sci. 2019 Aug 06;49(4):1095-1101
pubmed: 31385489
Sci Rep. 2019 Oct 22;9(1):15150
pubmed: 31641235
Health Qual Life Outcomes. 2011 Jul 19;9:54
pubmed: 21771304
Health Qual Life Outcomes. 2010 Mar 20;8:31
pubmed: 20302662
Int J Gen Med. 2011;4:681-6
pubmed: 22069368
Front Mol Neurosci. 2018 Nov 21;11:427
pubmed: 30534051
World J Biol Psychiatry. 2020 Nov 12;:1-29
pubmed: 33040669
J Electromyogr Kinesiol. 2013 Oct;23(5):1082-9
pubmed: 23800438
World J Psychiatry. 2019 Jan 4;9(1):1-6
pubmed: 30631748
Psychol Res Behav Manag. 2020 Nov 09;13:929-937
pubmed: 33204186
J Laryngol Otol. 2010 Jul;124(7):774-7
pubmed: 20307357
Scand J Pain. 2018 Apr 25;18(2):321-331
pubmed: 29794305
Int J Psychophysiol. 2020 Dec;158:136-142
pubmed: 33080288
Georgian Med News. 2019 Jul-Aug;(292-293):102-108
pubmed: 31560673
Behav Res Ther. 1995 Mar;33(3):335-43
pubmed: 7726811
Ups J Med Sci. 2017 Jun;122(2):99-107
pubmed: 28503982
Dialogues Clin Neurosci. 2002 Sep;4(3):231-49
pubmed: 22033741
Patient Prefer Adherence. 2011;5:581-6
pubmed: 22163157
Neuropsychiatr Dis Treat. 2019 Feb 13;15:469-480
pubmed: 30858704
Physiother Res Int. 2018 Jul;23(3):e1712
pubmed: 29536618
J Neurophysiol. 2010 Apr;103(4):1735-40
pubmed: 20107115
J Alzheimers Dis. 2013;36(2):297-302
pubmed: 23603397
Ther Clin Risk Manag. 2012;8:73-8
pubmed: 22368448
Psychol Med. 2002 Aug;32(6):1009-20
pubmed: 12214782
Pain Res Manag. 2018 Sep 25;2018:3259431
pubmed: 30356353
Front Hum Neurosci. 2013 Jun 28;7:317
pubmed: 23825454
Int Marit Health. 2014;65(2):65-7
pubmed: 25231328
Indian J Med Res. 2010 Aug;132:189-94
pubmed: 20716819
J Alzheimers Dis. 2014;42(1):325-32
pubmed: 24898637
Patient Prefer Adherence. 2012;6:195-9
pubmed: 22536055
Brain Stimul. 2016 May-Jun;9(3):336-346
pubmed: 27090022
Neuropsychiatr Dis Treat. 2012;8:149-54
pubmed: 22536071
J Clin Psychiatry. 2018 Jan/Feb;79(1):
pubmed: 28541649
Pan Afr Med J. 2016 May 27;24:89
pubmed: 27642428
Clin Neurophysiol. 2017 Jan;128(1):56-92
pubmed: 27866120
Sci Rep. 2014 Jul 11;4:5668
pubmed: 25011544
Int J Neuropsychopharmacol. 2013 Feb;16(1):13-21
pubmed: 22310245
Resuscitation. 1976;5(1):19-30
pubmed: 1087042
Ergonomics. 2013;56(7):1125-33
pubmed: 23713612
Front Neurol. 2019 Jun 11;10:549
pubmed: 31244747
Neuroimage. 2010 Nov 1;53(2):769-76
pubmed: 20600966
J Neurosci. 2015 Dec 2;35(48):15800-11
pubmed: 26631463
Neuropsychiatr Dis Treat. 2011;7:649-54
pubmed: 22090800
Neuropsychiatr Dis Treat. 2011;7:449-55
pubmed: 21857785